Cargando...
Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2
The control of micrometastatic breast cancer remains problematic. To this end, we are developing a new adjuvant therapy based on (213)Bi-PAI2, in which an α-emitting nuclide ((213)Bi) is chelated to the plasminogen activator inhibitor-2 (PAI2). PAI2 targets the cell-surface receptor bound urokinase...
Gardado en:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group
2003
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2377077/ https://ncbi.nlm.nih.gov/pubmed/12644835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600838 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|